Anhui CTSMED Pharmaceutical Technology

Anhui CTSMED Pharmaceutical Technology is a clinical-stage biotechnology company based in Hefei, China, dedicated to the discovery and development of next-generation small molecule therapeutics. The company leverages its proprietary Proteolysis Targeting Chimera (PROTAC) platform to develop degraders for previously undruggable protein targets involved in cancer and metabolic syndromes. CTSMED was established as a high-tech enterprise by a team of prominent scientists from the Chinese Academy of Sciences, ensuring a strong foundation in structural biology and medicinal chemistry. Its lead candidate, CG-001, is currently undergoing clinical evaluation for the treatment of advanced solid tumors. The company aims to deliver innovative, high-value medicines to meet significant unmet medical needs globally.